Heterocyclic N-Oxides - An emerging class of therapeutic agents

Current Medicinal Chemistry

Volumn 22, Issue 24, 2015, Pages 2819-2857

  Mfuh, A M ^a   Larionov, O V ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Antichagasic agents; Antimalarials; Bioisosteres; Coagulation cascade direct thrombin inhibitors; Factor xa inhibitors; Heterocyclic N oxides; Hypoxia; Nitric oxide mimics

Indexed keywords

1,7 NAPHTHYRIDINE N OXIDE; AGRICULTURAL CHEMICAL; AMINOPYRIDINE; AMINOPYRIDINE DERIVATIVE; ANCRIVIROC; BENZODIAZEPINE DERIVATIVE; CARBONYL DERIVATIVE; CHLORDIAZEPOXIDE; FURAZAN DERIVATIVE; GUANINE 7 OXIDE; HETEROCYCLIC COMPOUND; HETEROCYCLIC N OXIDE; HYPOXANTHINE 7 N OXIDE; HYPOXANTHINE DERIVATIVE; KOPEXIL; MINOXIDIL; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NAPHTHYRIDINE DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE DONOR; OTAMIXABAN; PYRIDINE 1 OXIDE; THROMBIN INHIBITOR; TIRAPAZAMINE; UNCLASSIFIED DRUG; AMINE OXIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; FIBRINOLYTIC AGENT; HERBICIDE; NEUROPROTECTIVE AGENT; PROTEIN KINASE INHIBITOR;

ANIMAL HUSBANDRY; ARTICLE; BLOOD CLOTTING; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HERBICIDAL ACTIVITY; HYPOXIA; MEDICINAL CHEMISTRY; NEUROPROTECTION; ANIMAL; HUMAN;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS; CYCLIC N-OXIDES; FIBRINOLYTIC AGENTS; HERBICIDES; HUMANS; NEUROPROTECTIVE AGENTS; PROTEIN KINASE INHIBITORS;

EID: 84940847525     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150619104007     Document Type: Article

References (247)

1. Schreiber, S.L. Organic synthesis toward small-molecule probes and drugs. Proc. Nat. Acad. Sci. U.S.A., 2011, 108, 6699-6702.
2. Stockwell, B.R. Exploring biology with small organic molecules. Nature, 2004, 432(7019), 846-854.
3. Ray, R.S.; Corcoran, A. E.; Brus, R.D.; Kim, J.C.; Richerson, G.B.; Nattie, E.; Dymecki, S.M. Impaired respiratory and body temperature control upon acute serotonergic neuron inhibition. Science, 2011, 333, 637-642.
4. Welsch, M.E.; Snyder, S.A.; Stockwell, B.R. Privileged scaffolds for library design and drug discovery. Curr. Opin. Chem. Biol., 2010, 14(3), 347-361.
5. DeSimone, R.W.; Currie, K.S.; Mitchell, S. A.; Darrow, J.W.; Pippin, D.A. Privileged structures: Applications in drug discovery. Comb. Chem. High Throughput Screen., 2004, 7(3), 473-493.
6. Dai, W.-M. Generation of molecular shape diversity. from privileged scaffolds to diverted total synthesis. Diver.-Orient. Synth., 2012, 1, 11-20.
7. Fishman, M.C.; Porter, J.A. Pharmaceuticals: A new grammar for drug discovery. Nature, 2005, 437(7058), 491-493.
8. Showell, G.A.; Mills, J.S. Chemistry challenges in lead optimization: silicon isosteres in drug discovery. Drug Discov. Today, 2003, 8(12), 551-556.
9. Vagner, J.; Qu, H.; Hruby, V.J. Peptidomimetics, a synthetic tool of drug discovery. Curr. Opin. Chem. Biol., 2008 12(3), 292- 296.
10. Meanwel, N.A. Synopsis of some recent tactical application of bioisosteres in drug design. J. Med. Chem., 2011, 54(8), 2529-2591.
11. Lackey, K.E. Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor. Curr. Top. Med. Chem., 2006, 6(5), 435-460.
12. Guertin, K.R.; Choi, Y-M. The discovery of the factor Xa inhibitor otamixaban: from lead identification to clinical development. Curr. Med. Chem., 2007, 14(23), 2471-2481.
13. Chaykin, S.; Bloch, K. The metabolism of nicotinamide-N-oxide. Biochim. Biophys. Acta, 1959, 31(1), 1213-1216.
14. Ihsan, A.; Wang, X.; Tu H-G.; Zhang, W.; Dai, M-H.; Peng, D-P.; Wang, Yu-L.; Huang, L-L.; Chen, D.-M.; Mannan, S.; Tao, Y-F.; Liu, Z-L.; Yuan, Z-H. Genotoxicity evaluation of mequindox in different short-term tests. Food Chem. Toxicol., 2013, 51, 330-336.
15. Palani, A.; Tagat, J.R. Discovery and development of smallmolecule chemokine coreceptor CCR5 antagonists. J. Med. Chem., 2006, 49, 2851-2856.
16. Debnath, A.K. Generation of predictive pharmacophore models for CCR5 antagonists: Study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors. J. Med. Chem., 2003, 46, 4501-4515.
17. Tagat, J.R.; Steensm, R.W.; McCombie, S.W.; Dennis, V.; Nazaren, D.V.; Lin, S-L.; Neustadt, B.R.; Cox, K.; Xu, S.; Wojcik, L.; Murray, M.G.; Vantuno, N.; Baroudy, B.M.; Strizki, J.M. Piperazine-based CCR5 antagonists as HIV-1 Inhibitors. II. Discovery of 1- [(2, 4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4- [3(S)- methyl-4- [1(S)- [4-(trifluorome-thyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist. J. Med. Chem., 2001, 44, 3343-3346.
18. Ganley, B.; Chowdhury, G.; Bhansali, J.; Daniels, J.S.; Gates, K.S. Redox-activated, hypoxia-selective DNA cleavage by quinoxaline 1, 4-di-N-oxide. Bioorg. Med. Chem., 2001, 9, 2395-2401.
19. Miroshnikova, O.V.; Hudson, T.H.; Gerena, L.; Kyle, D.E.; Lin, A.J. Synthesis and antimalarial activity of new isotebuquine analogues. J. Med. Chem., 2007, 50, 889-896.
20. Ibrahim, H.; Furiga, A.; Najahi, E.; Pigasse Henocq, C.; Nallet, J.P.; Roques, C.; Aubouy, A.; Sauvain, M.; Constant, P.; Daffe, M.; Nepveu, F. Antibacterial, antifungal and antileishmanial activities of indolone-N-oxide derivatives. J. Antibiot., 2012, 65(10), 499- 504.
21. Cerecetto, H.; Dias, E.; Di Maio, R.; Gonzalez, M.; Pacce, S.; Saenz, P.; Seoane, G. Synthesis and herbicidal activity of N-oxide derivatives. J. Agric. Food Chem., 2000, 48, 2995-3002.
22. Messenger, A.G.; Rundegren, J. Minoxidil: mechanisms of action on hair growth. Br. J. Dermatol., 2004, 150, 186-194.
23. Padois, K.; Cantien, C.; Bertholle, V. Solid lipid nanoparticles suspension versus commercial solutions for dermal delivery of minoxidil. Int. J. Pharm., 2011, 416, 300-304.
24. Rand, M.J.; Li, C.G. Nitric oxide as a neurotransmitter in peripheral nerves: nature of transmitter and mechanism of transmission. Ann. Rev. Physiol., 1995, 57, 659-682.
25. Bult, H.; Boeckxstaens, G.E.; Pelckmans, P.A.; Jordaens, F.H.; Van Maercke, Y.M.; Herman, A.G. Nitric oxide as an inhibitory non-adrenergic noncholinergic neurotransmitter. Nature, 1990, 345, 346-347.
26. Li, M.; Marubayashi, A.; Nakaya, Y.; Fukui, K.; Arase, S. Minoxidil- induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J. Invest. Dermatol., 2001, 117, 1594- 1600.
27. Johnson, G.A.; Barsuhn, K.J.; McCall, J.M. Sulfation of minoxidil by liver sulfotransferase. Biochem. Pharmacol., 1982, 31, 2949-2954.
28. Davies, G.C.; Thornton, M.J.; Jenner, T.J.; Chen, Y.J.; Hansen, J.B.; Carr, R.D.; Randall, V.A. Novel and established potassium channel openers stimulate hair growth in vitro: implications for their modes of action in hair follicles. J. Invest. Dermatol., 2005, 124(4), 686-694.
29. Weisman, M.; Furst, D.; Schiff, M.; Kauffman, R.; Merica, E.; Martin-Munley, S. A double-blind, placebo-controlled trial of VX- 745, an oral p38 mitogen activated protein kinase (MAPK) inhibitor, in patients with rheumatoid arthritis (RA). Present at EULAR 2002. Stockholm, Sweden. Abstract FRI0018. Ann. Rheum. Dis., 2002, 61, (Suppl. 2), 166.
30. Burgey, C.S.; Robinson, K.A.; Lyle, T.A.; Sanderson, P.E.J.; Lewis, S.D.; Lucas, B.J.; Krueger, J.A.; Singh, R.; Miller-Stein, C.; White, R.B.; Wong, B.; Lyle, E.A.; Williams, P.D.; Coburn, C.A.; Dorsey, B.D.; Barrow, J.C.; Stranieri, M.T.; Holahan, M.A.; Sitko, G.R.; Cook, J.J.; McMasters, D.R.; McDonough, C.M.; Sanders, W.M.; Wallace, A.A.; Clayton, F.C.; Bohn, D.; Leonard, Y.M. Jr.; Detwiler, T.J. Jr.; Lynch, J.J. Jr.; Yan, Y.; Chen, Z.; Kuo, L.; Gardell, S.J.; Shafer, J.A.; Vacca, J.P. Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines. J. Med. Chem., 2003, 46, 461-473.
31. Anderson, R.F.; Shinde, S.S.; Hay, M.P.; Gamage, S.A.; Denny, W.A. Potentiation of the cytotoxicity of the anticancer agent tirapazamine by benzotriazine N-oxides: The role of redox equilibria. J. Am. Chem. Soc., 2003, 125, 748-756.
32. Shinde, S.S.; Anderson, R.F.; Hay, M.P.; Gamage, S.A.; Denny, W.A. Oxidation of 2- deoxyribose by benzotriazinyl radicals of antitumor 3-amino-1, 2, 4- benzotriazine 1, 4-dioxides. J. Am. Chem. Soc., 2004, 126, 7853- 7864.
33. Wang, J.; Biedermann, K.A.; Brown, J.M. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res., 1992, 52, 4473-4477.
34. Siim, B.G.; van Zijl, P.L.; Brown, J.M. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. Br. J. Cancer, 1996, 73, 952-960.
35. Siim, B.G.; Menke, D.R.; Dorie, M.J.; Brown, J.M. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res., 1997, 57, 2922-2928.
36. Peters, K.B.; Brown, J.M. Tirapazamine. Cancer Res., 2002, 62, 5248-5253.
37. Evans, J.W.; Chernikova, S.B.; Kachnic, L.A.; Banath, J.P.; Sordet, O.; Delahoussaye, Y.M.; Treszezamsky, A.; Chon, B.H.; Feng, Z.; Gu, Y.; Wilson, W.R.; Pommier, Y.; Olive, P.L.; Powell, S.N.; Brown, J.M. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res., 2008, 68, 257-265.
38. Daniels, J.S.; Gates, K.S. DNA cleavage by the antitumor agent 3-amino-1, 2, 4-benzotriazine 1, 4-dioxide (SR4233): Evidence for involvement of hydroxyl radical. J. Am. Chem. Soc., 1996, 118, 3380-3385.
39. Kotandeniya, D.; Ganley, B.; Gates, K. Oxidative DNA base damage by the antitumor agent 3-amino-1, 2, 4- benzotriazine 1, 4-dioxide (Tirapazamine). Bioorg. Med. Chem. Lett., 2002, 12, 2325-2329.
40. Zagorevskii, D.; Song, M.; Breneman, C.; Yuan, Y.; Fuchs, T.; Gates, K.S.; Greenlief, C.M. A mass spectrometry study of tirapazamine and its metabolites: insights into the mechanism of metabolic transformations and characterization of reaction intermediates. J. Am. Soc. Mass Spectrom., 2003, 14, 881-892.
41. Schiefer, I.T.; VandeVrede, L.; Fa', M.; Arancio, O.; Thatcher, G.R.J. Furoxans (1, 2, 5-oxadiazole-N-oxides) as novel NO mimetic neuroprotective and procognitive agents J. Med. Chem., 2012, 55, 3076-3087.
42. Thatcher, G.R.J.; Bennett, B.M.; Reynolds, J.N. NO chimeras as therapeutic agents in Alzheimer's disease. Curr. Alzheimer Res., 2006, 3, 237-245.
43. Cena, C.; Boschi, D.; Tron, G.C.; Chegaev, K.; Lazzarato, L.; Di Stilo, A.; Aragno, M.; Fruttero, R.; Gasco, A. Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants. Bioorg. Med. Chem. Lett., 2004, 14, 5971-5974.
44. Zins, G.R. The history of the development of minoxidil. Clin. Dermatol., 1988, 6, 132-147.
45. Buhl, A.E.; Waldon, D.J.; Baker, C.A.; Johnson, G.A. Minoxidil sulfate is the active metabolite that stimulates hair follicles. J. Invest. Dermatol., 1990, 95, 553-557.
46. Harmon, C.S.; Ducote, L.D. Potassium channel openers stimulate DNA synthesis in mouse epidermal keratinocyte and whole hair follicle cultures. J. Skin Pharmacol., 1993, 6, 170-178.
47. Johnson, G. A.; Barsuhn, K.J.; McCall, J.M. Sulfation of minoxidil by liver sulfotransferase. Biochem. Pharmacol., 1982, 31, 2949-2954.
48. Fleishaker, J.C.; Andreadis, N.A.; Welshma, I.R.; Wright, C.E. The pharmacokinetics of 2.5- to 10-mg oral doses of minoxidil in healthy volunteers. J. Clin. Pharmacol., 1989, 29, 162-167.
49. Thoma, R.C.; Harpootlian, H. Metabolism of minoxidil, a new hypotensive agent I: Absorption, distribution, and excretion following administration to rats, dogs, and monkeys. J. Pharm. Sci., 1975, 64, 1366-1371.
50. Johnson, G.A.; Barsuhn, K.J.; McCall, J.M. Sulfation of minoxidil by liver sulfotransferase. Biochem. Pharmacol., 1982, 31, 2949-2954.
51. Meisheri, K.D.; Johnson, G.A.; Puddington, L. Enzymatic and non-enzymatic sulfation mechanisms in the biological actions of minoxidil. Biochem. Pharmacol., 1993, 45, 271-279.
52. Falany, C.N.; Kerl, E.A. Sulfation of minoxidil by human liver phenol sulfotransferase. Biochem. Pharmacol., 1990, 40, 1027- 1032.
53. Johnson, G.A.; Baker, C.A. Sulfation of minoxidil by human platelet sulfotransferase. Clin. Chim. Acta, 1987, 169, 217-227.
54. Johnson, G.A.; Baker, C.A.; Knight, K.A. Minoxidil sulfotransferase, a marker of human keratinocyte differentiation. J. Invest. Dermatol., 1992, 98, 730-733.
55. Anderson, R.; Kudlacek, P.E.; Clemens, D.L. Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem. Biol. Interact., 1998, 109, 53-67.
56. Dooley, T.P. Molecular biology of the human cytosolic sulfotransferase gene superfamily implicated in the bioactivation of minoxidil and cholesterol in skin. Exp. Dermatol., 1999, 8, 328-329.
57. Buhl, A.E.; Baker, C.A.; Dietz, A.J. Minoxidil sulfotransferase activity influences the efficacy of rogaine topical solution (TS): enzyme studies using scalp and platelets. J. Invest. Dermatol., 1994, 102, 534.
58. Babenko, A.P.; Aguilar-Bryan, L.; Bryan, J. A view of sur/KIR6.X, KATP channels. Annu. Rev. Physiol., 1998, 60, 667- 687.
59. Ashcroft, F.M.; Gribble, F.M. J. Diabetes Complicat., 2000, 14, 192-196.
60. McCall, J.M.; TenBrink, R.E.; Ursprung, J.J. New approach to triaminopyrimidine N-oxides. J. Org. Chem., 1975, 40(22), 3304- 3306.
61. Anthony, W.C.; Ursprung, J.J. 6-Amino-1, 2-dihydro-1-hydroxy-2- imino-4-phenoxypirimidines. US Patent 3, 382, 247. November 1, 1965.
62. Anthony, W.C. Compounds and process. US Patent 3, 644, 364. March 31, 1970.
63. Skerritt, J.H.; Johnston, G.A. Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur. J. Pharmacol., 1983, 89, 193-198.
64. Ban, T.A. The role of serendipity in drug discovery. Dialogues Clin. Neurosci., 2006, 8, 335-344.
65. Sternbach, L.; Stempe, R.A.; Rachlin, A. Quinazolines and 1, 4- benzodiazepines. XIV. Synthesis and transformation of 5-phenyl- 1, 4-benzodiazepine-2-thiones. J. Org. Chem., 1964, 29, 3744-3744.
66. Greenblatt, D.J.; Shader, R.I.; MacLeod, S.M.; Sellers, E.M. Benzodiazepines: A summary of pharmacokinetic properties. Clin. Pharmacokinet., 1978, 3, 381-394.
67. Campo-Soria, C.; Chang, Y.; Weiss, D.S. Mechanism of action of benzodiazepines on GABAA receptors. Br. J. Pharmacol., 2006, 148, 984-990.
68. Derry, J.M.; Dunn, S.M.; Davies, M. Identification of a residue in the gamma-aminobutyric acid type A receptor alpha subunit that differentially affects diazepam-sensitive and -insensitive benzodiazepine site binding. J. Neurochem., 2004, 88, 1431-1438.
69. Seymour, V.A.; Curmi, J.P.; Howitt, S.M.; Casarotto, M.G.; Laver, D.R.; Tierney, M.L. Selective modulation of different GABAA receptor isoforms by diazepam and etomidate in hippocampal neurons. Int. J. Biochem. Cell Biol., 2012, 44, 1491-1500.
70. Mohler, H. Role of GABAA receptors in cognition. Biochem. Soc. Trans., 2009, 37, 1328-1333.
71. Sigel E. Mapping of the benzodiazepine recognition site on GABAA receptors. Curr. Top. Med. Chem., 2002, 2, 833-839.
72. Jacob, T.C.; Moss, S.J.; Jurd, R. GABAA receptor trafficking and its role in the dynamic modulation of neuronal inhibition. Nat. Rev. Neurosci., 2008, 9, 331-343.
73. Akabas, M.H. GABAA receptor structure-function studies: A reexamination in light of new acetylcholine receptor structures. Int. Rev. Neurobiol., 2004, 62, 1-43.
74. Hanson, S.M.; Czajkowski, C. Structural mechanisms underlying benzodiazepine modulation of the GABAA receptor. J. Neurosci., 2008, 28(13), 3490-3499.
75. Sternbach, L.H.; Reeder, E.; Stempel, A.; Rachlin, A. Quinazolines and 1, 4-benzodiazepines. XVIII. The acetylation of chlordiazepoxide and its transformation into 6-chloro-4-phenyl-2- quinazoline-carboxaldehyde. J. Org. Chem., 1964, 29, 332-336.
76. Sternbach, L.H.; Reeder, E.; Stempel, A.; Rachlin, A. Additions and corrections - quinazolines and 1, 4-benzodiazepines. XVIII. The acetylation of chlordiazepoxide and its transformation into 6- chloro-4-phenyl-2-quinazolinecarboxaldehyde. J. Org. Chem., 1964, 29, 3744-3744.
77. Nutescu, E.A.; Pater, K. Drug evaluation: The directly activated factor Xa inhibitor otamixaban. IDrugs, 2006, 9, 854-865.
78. Hinder, M.; Frick, A.; Jordaan, P.; Hesse, G.; Gebauer, A.; Maas, J.; Paccaly, A. Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. Clin. Pharmacol. Ther., 2006, 80, 691-702.
79. Gould, W.R.; McClanahan, T.B.; Welch, K.M.; Baxi, S.M.; Saiya-Cork, K.; Chi, L.; Johnson, T.R.; Leadley, R.J. Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro. J. Thromb. Haemost., 2006, 4, 834-841.
80. Lillicrap, D.; Key, N.; Makris, M.; O'Shaughnessy, D. (2009). Practical Hemostasis and Thrombosis. Wiley-Blackwell. pp. 1-5.
81. Michiels, C. Endothelial cell functions. J. Cell Physiol., 2003, 196, 430-443.
82. Catella, F.; Healy, D.; Lawson, J.A.; FitzGerald, G.A. 11- Dehydrothromboxane B2: A quantitative index of thromboxane A2 formation in the human circulation. Proc. Nat. Acad. Sci. USA, 1986, 83, 5861-5865.
83. Gomez, K.; McVey, J.H.; Tissue factor initiated blood coagulation. Front. Biosci., 2006, 11, 1349-1359.
84. Bajaj, M.S.; Birktoft, J.J.; Steer, S.A.; Bajaj, S.P. Structure and biology of tissue factor pathway inhibitor. Thromb. Haemost., 2001, 86, 959-972.
85. Nesheim, M.E.; Taswell, J.B.; Mann, K.G. The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. J. Biol. Chem., 1979, 254, 10952-10962.
86. van Rijn, J.L.; Govers- Riemslag, J.W.; Zwaal, R.F.; Rosing, J. Kinetic studies of prothrombin activation: effect of factor Va and phospholipids on the formation of the enzyme-substrate complex. Biochemistry, 1984, 23, 4557-4564.
87. Mosesson, M.W. Fibrinogen and fibrin structure and functions. J. Thromb. Haemost., 2005, 3, 1894-1904.
88. Laki, K.; Lorand, L. On the solubility of fibrin clots. Science, 1948, 108(2802), 280.
89. Ariens, R.A.S.; Lai, T.S.; Weisel, J.W.; Greenberg, C.S.; Grant, P.G. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood, 2002, 100, 743-754.
90. Cesarman-Maus, G.; Hajjar, K.A. Molecular mechanisms of fibrinolysis. Br. J. Haematol., 2005, 129, 307-321.
91. Fabre, J.E.; Gurney, M.E. Limitations of current therapies to prevent thrombosis: A need for novel strategies. Mol. Biosyst., 2010, 6, 305-315.
92. Firestone, R.A.; Barker, P.L.; Pisano, J.M.; Asher, B.M.; Dahlgren, M.E. Monocyclic b-lactam inhibitors of human leukocyte elastase. Tetrahedron, 1990, 46(7), 2255-2262.
93. Knight, W.B.; Maycock, A.L.; Green, B.G.; Asher, B.M.; Gale, P.; Weston, H.; Finke, P.E.; Hagmann, W.K.; Shah, S.K.; Doherty, J.B. Mechanism of inhibition of human leukocyte elastase by two cephalosporin derivatives. Biochemistry, 1992, 31(21), 4980-4986.
94. Klein, S.I.; Czekaj, M.; Gardner, C.J.; Guertin, K.R.; Cheney, D.L.; Spada, A.P.; Bolton, S.A.; Brown, K.; Colussi, D.; Heran, C.L.; Morgan, S.R.; Leadley, R.J.; Dunwiddie, C.T.; Perrone, M.H.; Chu, V. Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa. J. Med. Chem., 1998, 41, 437-450.
95. Czekaj, M.; Klein, S.; Guertin, K.; Gardner, C.; Zulli, A.; Pauls, H.; Spada, A.; Cheney, D.; Brown, K.; Colussi, D.; Chu, V.; Leadley, R.; Dunwiddie, C. Optimization of the b-aminoester class of factor Xa inhibitors. Part 1: P(4) and side-chain modifications for improved in vitro potency. Bioorg. Med. Chem. Lett., 2002, 12, 1667- 1670.
96. Guertin, K.R.; Gardner, C.J.; Klein, S.I.; Zulli, A.L.; Czekaj, M.; Gong, Y.; Spada, A.P.; Cheney, D.L.; Maignan, S.; Guilloteau, J.- P.; Brown, K.D.; Colussi, D.J.; Chu, V.; Heran, C.L.; Morgan, S.R.; Bentley, R.G.; Dunwiddie, C.T.; Leadley, R.J.; Pauls, H.W. Optimization of the β-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent in vivo anticoagulant activity. Bioorg. Med. Chem. Lett., 2002, 12, 1671-1674.
97. Jarvis, L.M. AstraZeneca, Sanofi cut programs. Chem. Eng. News, 2013, 91(23), 17.
98. Chu, V.; Brown, K.; Colussi, D.; Gao, J.; Bostwick, J.; Kasiewski, C.; Bentley, R.; Morgan, S.; Guertin, K.; Pauls, H.W.; Gong, Y.; Zulli, A.; Perrone, M.H.; Dunwiddie, C.T.; Leadley, R.J. Pharmacological characterization of a novel factor Xa inhibitor, FXV673. Thromb. Res., 2001, 103, 309-324.
99. Singh, R.; Silva Elipe, M.V.; Pearson, P.G.; Arison, B.H.; Wong, B.K.; White, R.; Yu, X.; Burgey, C.S.; Lin, J.H.; Baillie, T.A. Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins. Chem. Res. Toxicol., 2003, 16, 198-207.
100. Subramanian, R.; Lin, C. C.; Ho, J.Z.; Pitzenberger, S.M.; Silva-Elipe, M.V.; Gibson, C.R.; Braun, M.P.; Yu, X.; Yergey, J.L.; Singh, R. Bioactivation of the 3-amino-6-chloropyrazinone ring in a thrombin inhibitor leads to novel dihydro-imidazole and imidazolidine derivatives: structures and mechanism using 13C-labels, mass spectrometry, and NMR. Drug Metab. Dispos., 2003, 31, 1437-14347.
101. Nantermet, P.G.; Burgey, C.S.; Robinson, K.A.; Pellicore, J.M.; Newton, C.L.; Deng, J.Z.; Selnick, H.G.; Lewis, S.D.; Lucas, B.J.; Krueger, J.A.; Miller-Stein, C.; White, R.B.; Wong, B.; McMasters, D.R.; Wallace, A.A.; Lynch, J.J.; Yan, Y.; Chen, Z.; Kuo, L.; Gardell, S.J.; Shafer, J.A.; Vacca, J.P.; Lyle, T.A. P2 pyridine Noxide thrombin inhibitors: A novel peptidomimetic scaffold. Bioorg. Med. Chem. Lett., 2005, 15, 2771-2775.
102. Lewis, S.D.; Ng, A.S.; Lyle, E.A.; Mellott, M.J.; Appelby, S.D.; Brady, S.F.; Stauffer, K.S.; Sisko, J.T.; Mao, S.-S.; Veber, D.F.; Nutt, R.F.; Lynch, J.J.; Cook, J.J.; Gardell, S.J.; Shafer, J.A. Inhibition of thrombin by peptides containing lysyl-alpha-keto carbonyl derivatives. Thromb. Haemostasis, 1995, 74, 1107-1112.
103. Piccione, G.; Casella, S.; Giannetto1, C; Giudice, E. Effect of storage conditions on prothrombin time, activated partial thromboplastin time and fibrinogen concentration on canine plasma samples. J. Vet. Sci., 2010, 11, 121-124.
104. Lumma, W.C.; Witherup, K. M.; Tucker, T. J.; Brady, S. F.; Sisko, J. T.; Naylor-Olsen, A. M.; Lewis, S. D.; Lucas, B. J.; Vacca, J. P. Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesis. J. Med. Chem., 1998, 41, 1011- 1013.
105. Tucker, T.J.; Lumma, W.C.; Lewis, S.D.; Gardell, S.J.; Lucas, B.J.; Baskin, E.P.; Woltmann, R.; Lynch, J.J.; Lyle, E.A.; Appleby, S.D.; Chen, I.-W.; Dancheck, K.B.; Vacca, J.P. Potent noncovalent thrombin inhibitors that utilize the unique amino acid d-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy. J. Med. Chem., 1997, 40, 1565-1569.
106. Boden, D.; Hurley, A.; Zhang, L.; Cao, Y.; Guo, Y.; Jones, E.; Tsay, J.; Ip, J.; Farthing, C.; Limoli, K.; Parkin, N.; Markowitz, M. HIV-1 drug resistance in newly infected individuals. J. Am. Med. Assoc., 1999, 282, 1135-1141.
107. Littman, D.R. Chemokine receptors: keys to AIDS pathogenesis? Cell, 1998, 93, 677-680.
108. Murphy, P.M. Viral exploitation and subversion of the immune system through chemokine mimicry. Nat. Immun., 2001, 2, 116-122.
109. Hunt, S.W. III; LaRosa, G. J. Chemokine receptors as HIV co-receptors: Targets for therapeutic intervention in AIDS. Annu. Rep. Med. Chem., 1998, 33, 263-270.
110. Saunders, J.; Tarby, C.M. Opportunities for novel therapeutic agents acting at chemokine receptors. Drug Discov. Today, 1999, 4, 80-92.
111. NIH, National Institute of Allergy and Infectious Diseases. Available from: (http://www.niaid.nih.gov/daids/dtpdb/attach.asp).
112. Cocchi, F.; DeVico, A.L.; Garzino-Demo, A.; Arya, S.K.; Gallo, R.C.; Lusso, P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science, 1995, 270, 1811-1815.
113. Michael, N.L.; Moore, J.P. HIV-1 entry inhibitors: evading the issue. Nat. Med., 1999, 5(7), 740-743.
114. Michael, N.L.; Chang, G.; Louie, L.G.; Mascola, J.R.; Dondero, D.; Birx, D. L.; Sheppard, H.W. The role of viral phenotype and CCR- 5 gene defects in HIV-1 transmission and disease progression. Nat. Med., 1997, 3(3), 338-340.
115. Maeda, K.; Yoshimura, K.; Shibayama, S.; Habashita, H.; Tada, H.; Sagawa, K.; Miyakawa, T.; Aoki, M.; Fukushima, D. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J. Biol. Chem., 2001, 276(37), 35194-35200.
116. Mastrolorenzo, A.; Scozzafava, A.; Supuran, C.T. Update on the development of HIV entry inhibitors. Expert Opin. Ther. Pat., 2001, 11, 1245-1252.
117. Palani, A.; Shapiro, S.; Josien, H.; Bara, T.; Clader, J.W.; Greenlee, W.J.; Cox, K.; Strizki, J.M.; Baroudy, B.M. Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti- HIV activity. J. Med. Chem., 2002, 45, 3143-3160.
118. Tagat, J.R.; McCombie, S.W.; Steensma, R.W.; Lin, S.-I.; Nazareno, D.V.; Baroudy, B.; Vantuno, N.; Xu, S.; Liu, J. Piperazinebased CCR5 antagonists as HIV-1 inhibitors I: 2(S)-methyl piperazine as a key pharmacophore element. Bioorg. Med. Chem. Lett., 2001, 11, 2143-2146.
119. Palani, A.; Shapiro, S.; Clader, J.W.; Greenlee, W.J.; Cox, K.; Strizki, J.; Endres, M.; Baroudy, B.M. Discovery of 4- [(Z)-(4- bromophenyl)-(ethoxyimino)methyl]-1'- [(2, 4-dimethyl-3-pyridinyl) carbonyl]-4'-methyl-1, 4'-bipiperidine N-oxide (SCH 351125): An orally bioavailable human CCR5 antagonist for the treatment of HIV infection. J. Med. Chem., 2001, 44(21), 3339-3342.
120. Strizki, J.M.; Xu, S.; Wagner, N.E.; Wojcik, L.; Liu, J.; Hou, Y.; Endres, M.; Palani, A.; Shapiro, S.; Clader, J.W.; Greenlee, W.J.; Tagat, J.R.; McCombie, S.; Cox, K.; Fawzi, A.B.; Chou, C.C.; Pugliese- Sivo, C.; Davies, L.; Moreno, M.E.; Ho, D.D.; Trkola, A.; Stoddart, C.A.; Moore, J.P.; Reyes, G.R.; Baroudy, B.M. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A., 2001, 98(22), 12718-12723.
121. Strizki J.M.; Tremblay, C.; Xu, S.; Wojcik, L.; Wagner, N.; Gonsiorek, W.; Hipkin, R.W.; Chou, C.C.; Pugliese-Sivo, C.; Xiao, Y.; Tagat, J.R.; Cox, K.; Priestley, T.; Sorota, S.; Huang, W.; Hirsch, M.; Reyes, G.R.; Baroudy, B.M. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 2005, 49, 4911-4919.
122. Fermini, B.; Fossa, A.A. The impact of drug-induced QT interval prolongation on drug discovery and development. Nat. Rev. Drug Discov., 2003, 2(6), 439-447.
123. Moller, C. Keeping the rhythm: hERG and beyond in cardiovascular safety pharmacology. Expert Rev. Clin. Pharmacol., 2010, 3, 321-329.
124. Vermeire, K.; Schols, D.; Bell, T.W. CD4 down-modulating compounds with potent anti-HIV activity. Curr. Pharm. Des., 2004, 10, 1795-1803.
125. Patterson, A.V.; Saunders, M.P.; Chinje, E.C.; Patterson, L.H.; Stratford, I.J. Enzymology of tirapazamine metabolism: A review. Anti-Cancer Drug Des., 1998, 13, 541-573.
126. Zeman, E.M.; Brown, J.M.; Lemon, M.J.; Hirst, V.K.; Lee, W.W. SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys., 1986, 12, 1239-1242.
127. Robbins, R.F.; Schofield, K. Polyazabicyclic compounds. Part II. Further derivatives of benzo-1, 2, 4-triazine. J. Chem. Soc., 1957, 3186-3194.
128. Ke, Q.; Costa, M. Hypoxia-Inducible Factor-1 (HIF-1). Mol. Pharmacol., 2006, 70, 1469-1480.
129. Maxwell, P.H.; Wiesener, M.S.; Chang, G.W.; Clifford, S.C.; Vaux, E.C.; Cockman, M.E.; Wykoff, C.C.; Pugh, C.W.; Maher, E.R.; Ratcliffe, P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 1999, 399, 271-275.
130. Semenza, G.L. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology, 2004, 19, 176-182.
131. Thomlinson, R.H.; Gray, L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer, 1955, 9, 539-549.
132. Wilson, W.R.; Hay, M.P. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer, 2011, 11, 393-410.
133. Marcu, L.; Bezak, E.; Olver, I. Scheduling cisplatin and radiotherapy in the treatment of squamous cell carcinomas of the head and neck: A modelling approach. Phys. Med. Biol., 2006, 51, 3625- 3637.
134. Brown, J.M.; Lemmon, M.J. Potentiation by the hypoxic cytotoxin SR-4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res., 1990, 50, 7745-7749.
135. Hay, M.P.; Gamage, S.A.; Kovacs, M.S.; Pruijn, F.B.; Anderson, R.F.; Patterson, A.V.; Wilson, W.R.; Brown, J.M.; Denny, W.A. Structure-activity relationships of 1, 2, 4-benzotriazine 1, 4-dioxides as hypoxia-selective analogues of tirapazamine. J. Med. Chem., 2003, 46, 169-182.
136. Hicks, K.O.; Siim, B.G.; Jaiswal, J.K.; Pruijn, F.B.; Fraser, A.M.; Patel, R.; Hogg, A.; Sarath Liyanage, H.D.; Dorie, M.J.; Brown, J.M.; Denny, W.A.; Hay, M.P.; Wilson, W.R. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogs with improved tissue penetration and hypoxic cell killing in tumors. Clin. Cancer Res., 2010, 16, 4946-4957.
137. Solano, B.; Junnotula, V.; Marin, A.; Villar, R.; Burguete A.; Vicente E.; Perez-Silanes, S.; Aldana, I.; Monge, A.; Dutta, S. Synthesis and biological evaluation of new 2-arylcarbonyl-3- trifluoromethyl-quinoxaline 1, 4-di-N-oxide derivatives and their reduced analogues. J. Med. Chem., 2007, 50, 5485-5492.
138. Jiang, F.Q.; Yang, B.; Fan, L.L.; He, Q.J.; Hu, Y.Z. Synthesis and hypoxic-cytotoxic activity of some 3-amino-1, 2, 4- benzotriazine-1, 4-dioxide derivatives. Bioorg. Med. Chem. Lett., 2006, 16, 4209-4213.
139. Xia, Q.; Zhang, L.; Zhang, J.; Sheng, R.; Yang, B.; He, Q.J.; Hu, Y.Z. Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1, 2, 4-benzotriazine-1, 4-dioxide derivatives. Eur. J. Med. Chem., 2011, 46, 919-926.
140. Jiang, F.Q.; Weng, Q.J.; Sheng, R.; Xia, Q.; He, Q.J.; Yang, B.; Hu, Y.Z. Synthesis, structure and hypoxic cytotoxicity of 3-amino-1, 2, 4-benzotriazine- 1, 4-dioxide derivatives. Arch. Pharm., 2007, 340, 258-263.
141. Sheng, R.; Xu, Y.; Weng, Q. J.; Xia, Q.; He, Q.J.; Yang, B.; Hu, Y.Z. Synthesis and cytotoxic activity of 3-phenyl-2-thioquinoxaline 1, 4-dioxide derivatives in hypoxia and in normoxia. Drug. Discov. Ther., 2007, 1, 119-123.
142. Weng, Q.J.; Wang, D.D.; Guo, P.; Fang, L.; Hu, Y.Z., He, Q.J.; Yang, B. Q39, a novel synthetic quinoxaline 1, 4-di-N-oxide compound with anti-cancer activity in hypoxia. Eur. J. Pharmacol., 2008, 581, 262-269.
143. Weng, Q.J.; Zhang, J.; Cao, J.; Xia, Q.; Wang, D.D.; Hu, Y.Z.; Sheng, R.; Wu, H.H.; Zhu, D.F.; Zhu, H.; He, Q.; Yang, B. Q39, a quinoxaline 1, 4- di-N-oxide derivative, inhibits hypoxia-inducible factor-1α expression and the Akt/mTOR/4E-BP1 signaling pathway in human hepatoma cells. Invest. New Drugs, 2011, 29, 1177-1187.
144. Hu, Y.; Xia, Q.; Shangguan, S.; Liu, X.; Hu, Y.; Sheng, R. Synthesis and biological evaluation of 3-aryl-quinoxaline-2-carbonitrile 1, 4-di-N-oxide derivatives as hypoxic selective anti-tumor agents. Molecules, 2012, 17, 9683-9696.
145. Nakashima, H.; Ikkyu, K.; Nakashima, K.; Sano, K.; Uto, Y.; Nakata, E.; Nagasawa, H.; Sugimoto, H.; Shiro, Y.; Nakagawa, Y.; Hori, H. Design of novel hypoxia-targeting IDO hybrid inhibitors conjugated with an unsubstituted L-TRP as an IDO affinity moiety. Adv. Exp. Med. Biol., 2010, 662, 415-421.
146. Nakashima, H.; Uto, Y.; Nakata, E.; Nagasawa, H.; Ikkyu, K.; Hiraoka, N.; Nakashima, K.; Sasaki, Y.; Sugimoto, H.; Shiro, Y.; Hashimoto, T.; Okamoto, Y.; Asakawa, Y.; Hori, H. Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2, 3-dioxygenase inhibitors. Bioorg. Med. Chem., 2008, 16, 8661-8669.
147. Adams Wilson, J.R.; Morandi, A.; Girard, T.D.; Thompson, J.L.; Boomershine, C.S.; Shintani, A.K.; Ely, E.W.; Pandharipande, P.P. The association of the kynurenine pathway of tryptophan metabolism with acute brain dysfunction during critical illness. Crit. Care Med., 2012, 40, 835-841.
148. Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van den Eynde, B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat. Med., 2003, 9, 1269- 1274.
149. Peters, K.B.; Wang, H.; Brown, J.M.; Iliakis, G. Inhibition of DNA replication by tirapazamine. Cancer Res., 2001, 61, 5425-5431.
150. Peters, K.B.; Brown, J.M. Tirapazamine: A hypoxia-activated topoisomerase II poison. Cancer Res., 2002, 62, 5248-5253.
151. Delahoussaye, Y.M.; Hay, M.P.; Pruijn, F.B.; Denny, W.A.; Brown, J.M. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting. Biochem. Pharmacol., 2003, 65, 1807-1815.
152. Delahoussaye, Y.M.; Evans, J.W.; Brown, J.M. Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem. Pharmacol., 2001, 62, 1201-1209.
153. Biedermann, K.A.; Wang, J.; Graham, R.P.; Brown, J.M. SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures. Br. J. Cancer, 1991, 63, 358-362.
154. Jones, G.D.; Weinfeld, M. Dual action of tirapazamine in the induction of DNA strand breaks. Cancer Res., 1996, 56, 1584-1590.
155. Daniels, J.S.; Gates, K.S.; Tronche, C.; Greenberg, M.M. Direct evidence for bimodal DNA damage induced by tirapazamine. Chem. Res. Toxicol., 1998, 11, 1254-1257.
156. Hwang, J.T.; Greenberg, M.M.; Fuchs, T.; Gates, K.S. Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1'- radical in single-stranded and double-stranded DNA: The drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA-damage reactions. Biochemistry, 1999, 38, 14248-14255.
157. Siim, B.G.; Pruijn, F.B.; Sturman, J.R.; Hogg, A.; Hay, M.P.; Brown, J.M.; Wilson, W.R. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317. Cancer Res., 2004, 64, 736-742.
158. Wada, T.; Penninger, J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene, 2004 23, 2838-2849.
159. Yang, D.P.; Kim, J.; Syed, N.; Tung, Y.J.; Bhaskaran, A.; Mindos, T.; Mirsky, R.; Jessen, K.R.; Maurel, P.; Parkinson, D.B.; Kim, H.A. p38 MAPK activation promotes denervated Schwann cell phenotype and functions as a negative regulator of Schwann cell differentiation and myelination. J. Neurosci., 2012, 32, 7158-7168.
160. Fernandes, D.J.; Ravenhall, C.E.; Harris, T.; Tran, T.; Vlahos, R.; Stewart, A.G. Contribution of the p38MAPK signalling pathway to proliferation in human cultured airway smooth muscle cells is mitogen- specific. Br. J. Pharmacol., 2004, 142, 1182-1190.
161. Svensson, C.; Part, K.; Kunnis-Beres, K.; Kaldmae, M.; Fernaeus, S.Z.; Land, T. Pro-survival effects of JNK and p38 MAPK pathways in LPS-induced activation of BV-2 cells. Biochem. Biophys. Res. Commun., 2011, 406, 488-492.
162. Sinfield, J.K.; Das, A.; O'Regan, D.J.; Ball, S.G.; Porter, K.E.; Turner, N.A. p38 MAPK alpha mediates cytokine-induced IL-6 and MMP-3 expression in human cardiac fibroblasts. Biochem. Biophys. Res. Commun., 2013, 430, 419-424.
163. Yong, H.Y.; Koh, M.S.; Moon, A. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin. Invest. Drugs, 2009, 18, 1893-1905.
164. Lee, J.C.; Laydon, J.T.; McDonnell, P.C.; Gallagher, T.F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M.J.; Heyes, J.R.; Landvatter, S.W.; Strickler, J.E.; McLaughlin, M.M.; Siemens, I.R.; Fisher, S.M.; Livi, G.P.; White, J.R.; Adams, J.L.; Young, P.R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature, 1994, 372, 739-746.
165. Fitzgerald, C.E.; Patel, S.B.; Becker, J.W.; Cameron, P.M.; Zaller, D.; Pikounis, V.B.; O'Keefe, S.J.; Scapin, G. Structural basis for p38 MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat. Struct. Biol., 2003, 10, 764-769.
166. Ferraciola, G. F. VX-745 Vertex Pharmaceutical. Curr. Opin. Anti- Inflam. Immunomodul. Invest. Drugs, 2000, 2, 74-77.
167. Haddad, J.J. VX-745 (Vertex Pharmaceuticals). Curr. Opin. Invest. Drugs, 2001, 2, 1070-1076.
168. Alonso-Alija, C.; Michels, M.; Schirok, H.; Schlemmer, K.-H.; Bell, J.; Fitzgerald, M.F.; Dodd, S.; Gill, A. Monocyclic aroylpyridinones as antiinflammatory agents. WO Patent 076405, September 4, 2003.
169. Schirok, H.; Alonso-Alija, C.; Benet-Buchholz, J.; Goller, A.H.; Grosser, R.; Michels, M.; Paulsen, H. Efficient regioselective synthesis of 6-amino-5-benzoyl-1-substituted 2(1H)- pyridinones. J. Org. Chem., 2005, 70, 9463-9469.
170. Zimmiti, C.S.; Schwartz, R.; Torcellini, C.A.; Pargellis, C.A.; Madwed, J.B.; Weldon, S.M. Suppression of p38 activity in vitro and THF alpha production in vivo with BIRB-796 BS, a novel p38 kinase inhibitor. Arthritis Rheum., 2001, 44, S114.
171. Regan, J.; Capolino, A.; Cirillo, P.F.; Gilmore, T.; Graham, A.G.; Hickey, E.; Kroe, R.R.; Madwed, J.; Moriak, M.; Nelson, R.; Pargellis, C.A.; Swinamer, A.; Torcellini, C.; Tsang, M.; Moss, N. Structureactivity relationships of the p38R MAP kinase inhibitor 1-(5-tert- Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3- [4-(2-morpholin-4-yl-ethoxy) napthalen-1-yl]urea (BIRB-796). J. Med. Chem., 2003, 46, 4676- 4686.
172. Devraj, R.V. Discovery and Development of Orally Active p38 Kinase Inhibitors as Anti-TNF Agents. In: Abstracts of Papers of the 229th National Meeting of the American Chemical Society, San Diego, CA, March 13-17, 2005; American Chemical Society: Washington, DC, 2005; MEDI-296.
173. Zack, D.J.; Campagnuolo, G.; Middleton, S.; Koch, A.; Zhu, L.; Bolon, B.; Feige, U. Efficacy of AMG 548, a Novel p38 Kinase Inhibitor, in Rats with Adjuvant-Induced or Collagen-Induced Arthritis. In: Abstracts of the 67th Annual Scientific Meeting of the American College of Rheumatology, Orlando, FL, October 23-28, 2003, Abstract 834.
174. Dominguez, C.; Liu, L.; Zhang, D.; Tamayo, N.; Powers, D.; Min, W.; Feige, F.; Harris, R.; Wild, S.; Neervannan, S.; Rashid, S.; Harvey, T. p38 MAP Kinase: An Exciting Target for the Treatment of Inflammatory Diseases. In: Abstracts of Papers of the 228th National Meeting of the American Chemical Society, Philadelphia, PA; American Chemical Society: Washington, DC, 2004; MEDI-189.
175. Nikas, S.N.; Drossos, A.A. SCIOS-469 (Scios Inc.). Curr. Opin. Investig. Drugs, 2004, 5, 1205-1212.
176. Lumeras, W.; Caturla, F.; Vidal, L.; Esteve, C.; Balague, C.; Orellana, A.; Dominguez, M.; Roca, R.; Huerta, J.M.; Godessart, N.; Vidal, B. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase. J. Med. Chem., 2009, 52, 5531-5545.
177. Lumeras, W.; Vidal, L.; Vidal, B., Balague, C.; Orellana, A.; Maldonado, M.; Dominguez, M.; Segarra, V.; Caturla, F. 1, 7- Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase. J. Med. Chem., 2011, 54, 7899-7910.
178. Walker, S.D.; Barder, T.E.; Martinelli, J.R.; Buchwald, S.L. A rationally designed universal catalyst for Suzuki-Miyaura coupling processes. Angew. Chem., Int. Ed., 2004, 43, 1871-1876.
179. Negishi, E.-I.; King, A.O.; Okukado, N. Selective carbon-carbon bond formation via transition-metal catalysis. 3. Highly selective synthesis of unsymmetrical biaryls and diarylmethanes by nickelcatalyzed or palladium-catalyzed reaction of aryl derivatives and benzylzinc derivatives with aryl. J. Org. Chem., 1977, 42, 1821- 1823.
180. Negishi, E.-I.; Luo, F.-T.; Frisbee, R.; Matsushita, H.A. Regiospecific synthesis of carbosubstituted heteroaromatic derivatives via Pd-catalyzed cross coupling. Heterocycles, 1982, 18, 117- 122.
181. Gasco, A.; Boulton, A.J. Furoxans and benzofuroxans. Adv. Heterocycl. Chem., 1981, 29, 251-340.
182. Fang, L.; Zhang, Y.; Lehmann, J.; Wang, Y.; Ji, H.; Ding, D. Design and synthesis of furoxan-based nitric oxide-releasing glucocorticoid derivatives with potent anti-inflammatory activity and improved safety. Bioorg. Med. Chem. Lett., 2007, 17, 1062-1066.
183. Olea-Azar, C.; Rigo, C.; Mendizabal, F.; Cerecetto, H.; Di Maio, R.; Gonzalez, M.; Porcal, W.; Morello, A.; Repetto, Y.; Maya, J.D.; Novel benzo [1, 2-c]1, 2, 5-oxadiazole N-oxide derivatives as antichagasic agents: chemical and biological studies. Lett. Drug Des. Discov., 2005, 4, 294-301.
184. Ghosh, P.B.; Whitehouse, M.W. 7-Chloro-4-nitrobenzo-2-oxa- 1, 3-diazole: A new fluorigenic reagent for amino acids and other amines. J. Med. Chem., 1968, 11, 305-311.
185. Whitehouse, M.W.; Ghosh, P.B. 4-Nitrobenzofurazans and 4-nitrobenzofuroxans: A new class of thiol-neutralising agents and potent inhibitors of nucleic acid synthesis in leucocytes. Biochem. Pharmacol., 1968, 17, 158-161.
186. Aguirre, G.; Boiani, M.; Cerecetto, H.; Fernandez, M.; Gonzalez, M.; Leon, E.; Pintos, C.; Raymondo, S.; Arredondo, C.; Pacheco, J.P.; Basombrio, M. Furoxan derivatives as cytotoxic agents: preliminary in vivo antitumoral activity studies. Pharmazie, 2006, 61, 54-59.
187. Boiani, L.; Aguirre, G.; Gonzalez, M.; Cerecetto, H.; Chidichimo, A.; Cazzulo, J.J.; Bertinaria, M.; Guglielmo, S. Furoxan-, alkylnitrate- derivatives and related compounds as anti-trypanosomatid agents: mechanism of action studies. Bioorg. Med. Chem., 2008, 16, 7900-7907.
188. Thatcher, G.R.J.; Nicolescu, A.C.; Bennett, B.M.; Toader, V. Nitrates and NO release: contemporary aspects in biological and medicinal chemistry. Free Radic. Biol. Med., 2004, 37, 1122-1143.
189. Zhuo, M.; Hu, Y.; Schultz, C.; Kandel, E. R.; Hawkins, R.D. Role of guanylyl cyclase and cGMP-dependent protein kinase in long-term potentiation. Nature, 1994, 368, 635-639.
190. Lu, Y.F.; Kandel, E.R.; Hawkins, R. D. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J. Neurosci., 1999, 19, 10250-10261.
191. Bon, C.L.; Garthwaite, J. On the role of nitric oxide in hippocampal long-term potentiation. J. Neurosci., 2003, 23, 1941-1948.
192. Haley, J.E.; Wilcox, G.L.; Chapman, P.F. The role of nitric oxide in hippocampal long-term potentiation. Neuron, 1992, 8, 211-216.
193. Cirelli, C.; Tonon, G. Differential expression of plasticity-related genes in waking and sleep and their regulation by the noradrenergic system. J. Neurosci., 2000, 20, 9187-9194.
194. Arancio, O.; Kiebler, M.; Lee, C.J.; Lev-Ram, V.; Tsien, R.Y.; Kandel, E.R.; Hawkins, R.D. Nitric oxide acts directly in the presynaptic neuron to produce long-term potentiation in cultured hippocampal neurons. Cell, 1996, 87, 1025-1035.
195. Gass, P.; Riva, M.A. CREB, neurogenesis and depression. Bioessays, 2007, 29, 957-961.
196. Peng, S.; Wu, J.; Mufson, E.J.; Fahnestock, M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J. Neurochem., 2005, 93, 1412-1421.
197. Rai, G.; Sayed, A.A.; Lea, W.A.; Luecke, H.F.; Chakrapani, H.; Prast-Nielsen, S.; Jadhav, A.; Leister, W.; Shen, M.; Inglese, J.; Austin, C. P.; Keefer, L.; Arner, E.S.; Simeonov, A.; Maloney, D.J.; Williams, D.L.; Thomas, C.J. Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. J. Med. Chem., 2009, 52, 6474-6483.
198. Sorba, G.; Medana, C.; Fruttero, R.; Cena, C.; Di Stilo, A.; Galli, U.; Gasco, A. Water soluble furoxan derivatives as NO prodrugs. J. Med. Chem., 1997, 40, 463-469.
199. Ferioli, R.; Folco, G.C.; Ferretti, C.; Gasco, A.M.; Medana, C.; Fruttero, R.; Civelli, M.; Gasco, A. A new class of furoxan derivatives as NO donors: mechanism of action and biological activity Br. J. Pharmacol., 1995, 114, 816-820.
200. Goldberg, M.P.; Strasser, U.; Dugan, L.L. Techniques for assessing neuroprotective drugs in vitro. Int. Rev. Neurobiol., 1997, 40, 69-93.
201. Lee, K.S.; Frank, S.; Vanderklish, P.; Arai, A.; Lynch, G. Inhibition of proteolysis protects hippocampal neurons from ischemia. Proc. Natl. Acad. Sci. U.S.A., 1991, 88, 7233-7237.
202. Bisby, R.H. Reactions of a free radical intermediate in the oxidation of amodiaquine. Biochem. Pharmacol., 1990, 39, 2051-2055.
203. Mott, B.T.; Cheng, K.C.; Guha, R.; Kommer, V.P.; Williams, D.L.; Vermeire, J.J.; Cappello, M.; Maloney, D.J.; Rai, G.; Jadhav, A.; Simeonov, A.; Inglese, J.; Posner, G.H.; Thomas, C.J. A furoxanamodiaquine hybrid as a potential therapeutic for three parasitic diseases. Medchemcomm., 2012, 12, 1505-1511.
204. Egan T.J. Quinoline antimalarials. Expert Opin. Ther. Pat., 2001, 11, 185-209.
205. Egan, T.J. Structure-function relationships in chloroquine and related 4-aminoquinoline antimalarials. Mini- Rev. Med. Chem., 2001, 1, 113-123.
206. Schmunis, G.A.; Yadon, Z.E. Chagas disease: A Latin American health problem becoming a world health problem. Acta Trop., 2010, 115(1-2), 14-21.
207. Cerecetto, H.; Gonzalez, M. Synthetic medicinal chemistry in Chagas' disease: compounds at the final stage of "Hit-To-Lead" phase. Pharmaceuticals, 2010, 3, 810-838.
208. Otero, L.; Vieites, M.; Boiani, L.; Denicola, A.; Rigol, C.; Opazo, L.; Olea-Azar, C.; Maya, J.D.; Morello, A.; Krauth-Siegel, R.L.; Piro, O.E.; Castellano, E.; Gonzalez, M.; Gambino, D.; Cerecetto, H. Novel antitrypanosomal agents based on palladium nitrofurylthiosemicarbazone complexes: DNA and redox metabolism as potential therapeutic targets. J. Med. Chem., 2006, 49, 3322-3331.
209. Gerpe, A.; Odreman-Nunez, I.; Draper, P.; Boiani, l.; Urbina, J.A.; Gonzalez, M.; Cerecetto, H. Heteroallyl-containing 5- nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action. Bioorg. Med. Chem., 2008, 16, 569-577.
210. Gerpe, A.; Alvarez, G.; Benitez, D.; Boiani, L.; Quiroga, M.; Hernandez, P.; Sortino, M.; Zacchino, S.; Gonzalez, M.; Cerecetto, H. 5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene. Bioorg. Med. Chem., 2009, 17, 7500-7509.
211. Porcal, W.; Hernandez, P.; Boiani, M.; Aguirre, G.; Boiani, L.; Chidichimo, A.; Cazzulo, J.J.; Campillo, N.E.; Paez, J.A.; Castro, A.; Krauth Siegel, R.L.; Davies, C.; Basombr, M.A.; Gonzalez, M.; Cerecetto, H. In vivo anti-chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives. J. Med. Chem., 2007, 50, 6004-6015.
212. Porcal, W.; Hernandez, P.; Boiani, L.; Boiani, M.; Ferreira, A.; Chidichimo, A.; Cazzulo, J.J.; Olea-Azar, C.; Gonzalez, M.; Cerecetto, H. New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle. Bioorg. Med. Chem., 2008, 16, 6995-7004;.
213. Merlino, A.; Benitez, D.; Chavez, S.; Da Cunha, J.; Hernandez, P.; Tinoco, L.W.; Campillo, N.E.; Paez, J.A.; Cerecetto, H.; Gonzalez, M. Development of second generation amidinohydrazones, thio- and semicarbazones as Trypanosoma cruzi-inhibitors bearing benzofuroxan and benzimidazole 1, 3-dioxide core scaffolds. Medchemcomm, 2010, 1, 216-228.
214. Merlino, A.; Benitez, D.; Campillo, N.E.; Paez, J.A.; Tinoco, L.W.; Gonzalez, M.; Cerecetto, H. Amidines bearing benzofuroxan or benzimidazole 1, 3-dioxide core scaffolds as Trypanosoma cruziinhibitors: structural basis for their interactions with cruzipain. Medchemcomm, 2012, 3, 90-101.
215. Clark, R.D. Synthesis and QSAR of herbicidal 3-pyrazolyl α, α, α-trifluorotolyl ethers. J. Agric. Food Chem., 1996, 44, 3643- 3652.
216. Nandihalli, U.B.; Duke, M.V.; Ashmore, J.A.; Musco, V.A.; Clark, R.D.; Duke, O.S. Enantioselectivity of protoporphyrinogen oxidase-inhibiting herbicides. Pestic. Sci., 1994, 40, 265- 277.
217. Kleschick, W.A.; Costales, M.J.; Dunbar, J.E.; Meikle, R.W.; Monte, W.T.; Pearson, N.R.; Snider, S.W.; Vinogradoff, A.P. New herbicidal derivatives of 1, 2, 4-triazolo [1, 5-a] pyrimidine. Pestic. Sci., 1990, 29, 341-355.
218. Wepplo, P. Imidazolinone herbicides: synthesis and novel chemistry. Pestic. Sci., 1990, 39, 293-315.
219. Baker, N.R.; Percival, M.P. Herbicides and Photosynthesis. In: Herbicides, . Topics in Photosynthesis; Elsevier Science Publishers: Amsterdam, The Netherlands, 1990, Vol. 10, pp. 1-26.
220. English, A.R., Dunegan, C.M. Quinoxaline-1, 4-di-N-oxides. I. Inhibition of deoxyribonucleic acid synthesis in Escherichia coli by 2, 3-dihydroxymethyl-quinoxaline-1, 4-di-N-oxide. Proc. Soc. Exp. Biol. Med., 1970 133, 398-400.
221. Suter, W.; Rosselet, A.; Knusel, F. Mode of action of quindoxin and substituted quinoxaline-di-Noxides on Escherichia coli. Antimicrob. Agents Chemother., 1978, 13, 770-783.
222. Kern, D.L.; Hokanson, G.C.; French, J.C.; Dally, N.K. Guanine- 7-oxide, a novel antitumor antibiotic. J. Antibiot., 1985, 38, 572-574.
223. Kitahara, M.; Ishii, K.; Kumada, Y.; Shiraishi, T.; Furuta, T.; Miwa, T.; Kawaharada, H.; Watanabe, K. 7- Hydroxyguanine, a novel anti-metabolite from a strain of Streptomyces purpurascens. I. Taxonomy of producing organism, fermentation, isolation and biological activity. J. Antibiot., 1985, 38, 972- 976.
224. Kitahara, M.; Ishii, K.; Kawaharada, H.; Watanabe, K.; Suga, T.; Hirata, T.; Nakamura, S. 7-Hydroxyguanine, a novel antimetabolite from a strain of Streptomyces purpurascens. II. Physico- chemical properties and structure determination. J. Antibiot., 1985, 38, 977-980.
225. Nishii, M.; Inagaki, J.; Nohara, F.; Isono, K.; Kusakabe, H.; Kobayashi, K.; Sakurai, T.; Koshimura, S.; Sethi, S.K.; McCloskey, J.A. A new antitumor antibiotic, guanine 7-N-oxide produced by Streptomyces sp. J. Antibiot., 1985, 38, 1440-1443.
226. Jackson, R.C.; Boritzki, T.J.; Besserer, J.A.; Hamelehle, K.L.; Shillis, J.L.; Leopold, W.R.; Fry, D.W. Biochemical pharmacology and experimental chemotherapy studies with guanine-7-oxide, a novel purine antibiotic. Adv. Enzyme Regul., 1987, 26, 301-316.
227. Hasobe, M.; Saneyoshi, M.; Isono, K. Antiviral activity and its mechanism of guanine 7-N-oxide on DNA and RNA viruses derived from salmonid. J. Antibiot., 1985, 38, 1581-1587.
228. Kanematsu, S.; Brown, G.B. Purine N-oxides. XIX. On the oncogenic N-oxide derivatives of guanine and xanthine and a nononcogenic isomer of xanthine N-oxide. Cancer Res., 1967, 27, 925-931.
229. Fujii, T.; Itaya, T.; Ogawa, K. The 7-N-oxides of purines related to nucleic acid: Their chemistry, synthesis and biological evaluation. Heterocycles, 1997, 44, 573-592.
230. Kitahara, M.; Ishii, K.; Kumada, Y.; Shiraishi, T.; Furuta, T.; Miwa, T.; Kawaharada, H.; Watanabe, K. 7-Hydroxyguanine, a novel antimetabolite from a strain of Streptomyces purpurascens. I. Taxonomy of producing organism, fermentation, isolation and biological activity. J. Antibiot., 1985, 38, 972-976.
231. Kitahara, M.; Shinjyo, K.; Fukae, M.; Hosoe, K.; Shiraishi, T.; Ishii, K.; Watanabe, K.; Kawaharada, H. Preparation of new 7- hydroxyguanine derivatives and their biological activities. J. Antibiot., 1990, 43, 352-356.
232. Ogawa, K.; Nishii, M.; Nohara, F.; Saito, T.; Itaya, T.; Fujii, T. Purines. Part 51. Synthesis and biological activity of hypoxanthine 7-N-oxide and related compounds. Chem. Pharm. Bull., 1992, 40, 612-616.
233. Fujii, T.; Ogawa, K.; Itaya, T.; Date, T.; Inagaki, J.; Nohara, F. Purines. LXX. An extension of the "phenacylamine route" to the syntheses of the 7-N-oxides of 6-mercaptopurine and 6-methylthiopurine, and antileukemic activity of some purine Noxides. Chem. Pharm. Bull., 1995, 43, 408-413.
234. Parra, K.V.; Adrian, J.C.; Gerlai, R. The synthetic substance hypoxanthine 3-N-oxide elicits alarm reactions in zebrafish (Danio rerio). Behav. Brain Res., 2009, 205, 336-341.
235. Nohara, F.; Nishii, M.; Ogawa, K.; Isono, K.; Ubukata, M.; Fujii, T.; Itaya, T.; Saito, T. Synthesis of guanine 7-oxide, an antitumor antibiotic from Streptomyces species. Tetrahedron Lett., 1987, 28, 1287-1290.
236. Albini, A. Heterocyclic N-oxides. CRC Press, 1991, chapter 4.
237. Groll, M.; Larionov, O.V.; Huber, R.; de Meijere, A. Inhibitorbinding mode of homobelactosin C to proteasomes: new insights into class I MHC ligand generation. Proc. Natl. Acad. Sci. U.S.A., 2006, 103(12), 4576-4579.
238. de Meijere, A.; Korotkov, V.S.; Lygin, A.V.; Larionov, O.V.; Sokolov, V.V.; Graef, T.; Es-Sayed, M. Synthesis and biological activity of simplified belactosin C analogues. Org. Biomol. Chem., 2012, 10(31), 6363-6374.
239. Carlin, R.L. Transition metal complexes of pyridine N-oxide. J. Am. Chem. Soc., 1961, 83(18), 3773-3775.
240. Popp, C.J.; Garlough, G.D. Transition metal complexes of diazine N-oxides. J. Inorg. Nucl. Chem., 1981, 43(3), 501-507.
241. Sarma, R.; Karmakar, A.; Baruah, J.B. Synthesis and characterization of pyridine N-oxide complexes of manganese, copper and zinc. Inorg. Chim. Acta, 2008, 361, 2081-2086.
242. Coperet, C.; Adolfsson, H.; Khuong, T.-A.W.; Yudin, A.K.; Sharpless, K.B. A simple and efficient method for the preparation of pyridine N-oxides. J. Org. Chem., 1998, 63, 1740-1741.
243. Larionov, O.V.; Stephens, D.; Mfuh, A.M.; Arman, H.D.; Naumova, A.S.; Chavez, G.; Skenderi, B. Insights into the mechanistic and synthetic aspects of the Mo/P-catalyzed oxidation of N-heterocycles. Org. Biomol. Chem., 2014, 12(19), 3026-3036.
244. Larionov, O.V.; Stephens, D.; Mfuh, A.; Chavez, G. Direct, catalytic, and regioselective synthesis of 2-alkyl-, aryl-, and alkenyl-substituted N-heterocycles from N-oxides. Org. Lett., 2014, 16(3), 864-867.
245. Stephens, D.E.; Chavez, G.; Valdes, M.; Dovalina, M.; Arman, H.D.; Larionov, O.V. Synthetic and mechanistic aspects of the regioselective base-mediated reaction of perfluoroalkyl- and perfluoroarylsilanes with heterocyclic N-oxides. Org. Biomol. Chem., 2014, 12(32), 6190-6199.
246. Stephens, D.E.; Lakey-Beitia, J.; Atesin, A.C.; Atesin, T.A.; Chavez, G.; Arman, H.D.; Larionov, O.V. Palladium-catalyzed C8-selective C-H arylation of quinoline N-oxides: insights into the electronic, steric and solvation effects on the site-selectivity by mechanistic and DFT computational studies. ACS Catal., 2015, 5(1), 167-175.
247. Stephens, D.E.; Lakey-Beitia, J.; Chavez, G.; Ilie, C.; Arman, H.D.; Larionov, O.V. Experimental and mechanistic analysis of the palladium- catalyzed oxidative C8-selective C-H homocoupling of quinoline N-oxides. Chem. Commun., 2015, 51, 9507-9510.